PIONEER 6: Cardiovascular Safety for the Tablet
Last verified May 2026 · Phase 3a · Finished; published June 2019 · NCT02692716 ↗
Oral semaglutide is the same molecule delivered through a much less efficient route: only a small fraction is absorbed, which is why Rybelsus requires the fasting window and why the milligram doses look so different from the injectable. The obvious question is whether that variability in absorption undermines the benefit the injection demonstrated. PIONEER 6 was designed to rule out harm rather than to prove benefit, and it did so, with the event counts pointing in the favorable direction.
- Enrollment
- 3,183
- Duration
- Run until enough events accumulated rather than to a fixed date, giving a median 15.9 months — far shorter than the multi-year trials it gets compared against
- Drug
- Oral semaglutide (up to 14 mg once daily)
- Population
- Adults with type 2 diabetes and an HbA1c of 7.0% or higher, entering either at 50 and over with established cardiovascular disease or reduced kidney function, or at 60 and over with risk factors alone. ⚠ 84.7% arrived with established disease. Average age 66, 31.6% women, average BMI 32.3, average HbA1c 8.2%, and nearly 15 years since diagnosis. 61% were on insulin — an advanced-disease population, not a newly diagnosed one.
Primary endpoint
Cardiac death, a nonfatal heart attack, or a nonfatal stroke — whichever came first
Treatment arm
61 of 1,591 (3.8%)
Comparator
76 of 1,592 (4.8%)
Treatment difference: Hazard ratio 0.79 (95% CI 0.57–1.11); P<0.001 for non-inferiority; P=0.17 for superiority
★ The trial cleared the bar it was built to clear: the tablet is not cardiovascularly worse than placebo. The 21% reduction in the point estimate is encouraging and was never testable — the confidence interval crossed 1, and this trial was sized for safety on a short timeline, not to prove benefit.
Secondary endpoints
| Endpoint | Treatment | Comparator | Difference |
|---|---|---|---|
| Death from a cardiac cause ⚠ A 51% reduction, which is the most eye-catching number on this page and the one most often quoted without its condition attached. The trial's own pre-set testing order had already stopped by this point, so this is a nominal finding rather than an established one — and it rests on 15 deaths against 30. | 15 of 1,591 (0.9%) | 30 of 1,592 (1.9%) | Hazard ratio 0.49 (95% CI 0.27–0.92) |
| Heart attacks that were not fatal ⚠ Numerically higher on the drug, on small numbers and a wide interval. A different pattern from the injectable semaglutide trial, and not something to read much into either way. | 37 of 1,591 (2.3%) | 31 of 1,592 (1.9%) | Hazard ratio 1.18 (95% CI 0.73–1.90) |
| Strokes that were not fatal Slightly fewer, with too few events over 16 months to say more. | 12 of 1,591 (0.8%) | 16 of 1,592 (1.0%) | Hazard ratio 0.74 (95% CI 0.35–1.57) |
| Death from any cause at all ⛔ The most contested figure in this trial: 23 deaths against 45, a 49% reduction. Large, with a confidence interval excluding 1 — and formally uninterpretable under the trial's own testing plan, on small numbers over a short follow-up. Treat anyone quoting it as proof this tablet saves lives with real caution. | 23 of 1,591 (1.4%) | 45 of 1,592 (2.8%) | Hazard ratio 0.51 (95% CI 0.31–0.84) |
| A wider count adding heart-failure and unstable-angina admissions Pointing the same way as the main result and not significant, with heart-failure admissions much the same in both arms. | 79 of 1,591 (5.0%) | 100 of 1,592 (6.3%) | Hazard ratio 0.82 (95% CI 0.61–1.10) |
| Three-month average blood sugar at six months A full point of improvement at the 14 mg dose — confirmation that the tablet does the glucose job, in a trial that was not built to measure that. | −1.0 percentage points | −0.3 percentage points | Estimated treatment difference −0.7 percentage points (95% CI not reported in primary paper; consistent with PIONEER glycemic-efficacy trials) |
| Weight change ⚠ About 4 kg. Meaningful, and nowhere near the weight-management doses of injected semaglutide. This is the diabetes tablet in an older, insulin-treated population. | −4.2 kg | −0.8 kg | Estimated treatment difference −3.4 kg |
| Confirmed low blood sugar ★ No excess from the drug itself. What causes lows here is the insulin that 61% of participants were already taking, and the sulfonylureas another 29% were on. | Rates broadly similar between arms (semaglutide did not increase hypoglycemia on its own) | Baseline rate from background insulin and sulfonylureas | No clinically meaningful imbalance reported |
| Stopped the drug early over a side effect ⚠ Roughly double placebo, concentrated while the dose was being raised. This has been a persistent real-world problem for the oral form specifically, and it belongs in any decision between a tablet and an injection. | 11.6% (185/1,591) | 6.5% (104/1,592) | Higher on oral semaglutide, driven by gastrointestinal events during titration |
Adverse events
| Event | Treatment rate | Comparator rate |
|---|---|---|
| Any serious adverse event ★ Lower on the drug than on placebo — mostly because a high-risk population had fewer cardiac events on it. | 18.9% (301/1,591) | 22.5% (358/1,592) |
| Stopped the drug over a side effect 11.6% against 6.5%, peaking in the four to eight weeks of dose escalation, and driven by stomach and bowel problems. | 11.6% (185/1,591) | 6.5% (104/1,592) |
| Nausea The most common complaint, mostly mild to moderate and early. The label puts it at roughly one in five patients at the 14 mg dose. | Higher on oral semaglutide than placebo (consistent with the PIONEER program; specific incidence not the headline endpoint in the safety publication) | Lower (placebo rate similar to other GLP-1 CVOT placebo arms) |
| Pancreatitis, confirmed by independent review One case against ten on placebo. No signal of increased risk. | 0.1% (1/1,591) | 0.6% (10/1,592) |
| Sudden kidney injury ⚠ Numerically higher on the drug and not statistically distinguishable. The usual explanation is dehydration from vomiting and diarrhea during titration — which is a practical reason to keep fluids up while the dose is climbing. | 1.5% (24/1,591) | 1.0% (16/1,592) |
| Diabetic eye disease getting worse ★ No significant excess here, unlike the injectable semaglutide trial, which found a clear one. The label still advises eye monitoring if you have retinopathy and your blood sugar is falling fast — the mechanism is the speed of improvement, not the formulation. | 7.1% (113/1,591) | 6.3% (101/1,592) |
| Cancers of any kind ⚠ Balanced between the arms — but 16 months is far too short for cancer risk to declare itself, so this is not reassurance about long-term use. | Rates balanced between arms over the trial period | Rates balanced between arms over the trial period |
Subgroup analyses
- People who arrived with established cardiovascular or kidney disease — about 85%: In line with the trial overall
This group made up nearly the whole trial and produced nearly all its events.
- People 60 and over with risk factors only — about 15%: Too few events to say anything
⚠ Not evidence of benefit or its absence. The trial was never sized to look here.
- Whether people were already on insulin: Same direction in both
61% were, which is a marker of how advanced this population's diabetes was.
- Where in the world people were enrolled: No clear differences across regions
Recruitment spanned 21 countries, though the event count in any one of them is small.
Clinical significance
For someone who cannot or will not inject, this is the trial establishing that the oral route is not a cardiovascular compromise. It should be read as safety rather than as an outcomes win — SOUL, the properly powered oral outcomes trial, is the one designed to answer superiority. ⚠ Note also that a non-inferiority finding at 15.9 months is a shorter window than the multi-year trials it is often compared against.
Who sells semaglutide, and for how much
This trial tested Oral semaglutide (up to 14 mg once daily). Across the 556 sellers on this register, 283 publish a standing monthly cash price for compounded semaglutide, from $79 a month, with a median of $174.
⛔ None of those sellers was in this trial. A compounded preparation is not the product studied here: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and its concentration is set by whichever pharmacy filled it. The result above is the strongest evidence available for semaglutide and it was generated on something else. Every seller, with its price record.
Frequently Asked Questions
References
- 1.Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019. PMID: 31185157.
- 2.Novo Nordisk A/S. A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6) — Study Results. ClinicalTrials.gov, NCT02692716. 2019. https://clinicaltrials.gov/study/NCT02692716
- 3.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. PMID: 27633186.
- 4.Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. PMID: 27295427.
- 5.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131.
- 6.Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
- 7.U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets — Prescribing Information (initial approval September 2019). FDA Drug Label. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf